Literature DB >> 8592951

Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats.

M Gunness1, E Orwoll.   

Abstract

Androgen deficiency is associated with low bone mass in humans and animals, but the remodeling alterations that lead to bone loss are unclear. Our objective was to define early responses in both cancellous and cortical bone to orchiectomy (ORX) using histomorphometry in sexually mature (4-month-old) rats. A total of 62 male rats, 4 months of age, were divided into six groups, sham operated (SH) or orchiectomized (ORX), and sacrificed 1, 2, or 4 weeks after ORX. Calcein was given 5 and 2 days before sacrifice to label mineralizing surfaces. Bone mineral density (BMD) was measured in excised femurs by dual energy X-ray absorptiometry (DEXA). Static and dynamic histomorphometry was evaluated in the cancellous bone of the proximal tibial metaphysis and lumbar vertebral bodies, and in the cortical bone of the tibial diaphysis. Osteopenia began to develop by 2 weeks after ORX, though weight gain and femur length did not change. Femoral BMD was significantly reduced and BMC decreased (NS) by 4 weeks after ORX (p < 0.05). Tibial and vertebral cancellous bone volume decreased 19% and 13%, respectively, while osteoblast and osteoclast surfaces, and numbers of osteoclasts, increased after ORX. At 2 weeks post-ORX, an increase in cancellous bone formation rate was attributable primarily to an increase in mineralizing surfaces and a smaller rise in mineral apposition rate. In contrast, cortical bone periosteal, but not endosteal, bone formation rate and mineralizing surfaces decreased. We conclude that ORX stimulates cancellous and diminishes periosteal bone turnover rapidly after ORX, with subsequent decreases in bone volume and mineral density. The clear divergence in cortical and cancellous bone responses to hypogonadism raises important questions regarding the control of bone formation and its role in defining the skeletal phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592951     DOI: 10.1002/jbmr.5650101117

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  15 in total

1.  Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats.

Authors:  Yankel Gabet; David Kohavi; Ralph Müller; Michael Chorev; Itai Bab
Journal:  Osteoporos Int       Date:  2005-04-06       Impact factor: 4.507

2.  Androgens regulate bone resorption activity of isolated osteoclasts in vitro.

Authors:  L Pederson; M Kremer; J Judd; D Pascoe; T C Spelsberg; B L Riggs; M J Oursler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Rodent models of osteoporosis.

Authors:  Antonia Sophocleous; Aymen I Idris
Journal:  Bonekey Rep       Date:  2014-12-10

Review 4.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 5.  Unresolved issues in osteoporosis in men.

Authors:  E Seeman
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

6.  Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes.

Authors:  Kristine M Wiren; Xiao-Wei Zhang; Dawn A Olson; Russell T Turner; Urszula T Iwaniec
Journal:  Bone       Date:  2012-08-14       Impact factor: 4.398

7.  Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration.

Authors:  Mami Ogita; Marie Therese Rached; Elzbieta Dworakowski; John P Bilezikian; Stavroula Kousteni
Journal:  Endocrinology       Date:  2008-07-10       Impact factor: 4.736

8.  Androgen receptors and experimental bone loss - an in vivo and in vitro study.

Authors:  Joao Paulo Steffens; Leila Santana Coimbra; Carlos Rossa; Alpdogan Kantarci; Thomas E Van Dyke; Luis Carlos Spolidorio
Journal:  Bone       Date:  2015-10-09       Impact factor: 4.398

Review 9.  Skeletal and extraskeletal actions of denosumab.

Authors:  Kathrin Sinningen; Elena Tsourdi; Martina Rauner; Tilman D Rachner; Christine Hamann; Lorenz C Hofbauer
Journal:  Endocrine       Date:  2012-05-13       Impact factor: 3.633

Review 10.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.